Zions Bancorporation National Association UT Takes $174,000 Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Key Points

• Zions Bancorporation National Association UT has purchased a new position in Alnylam Pharmaceuticals valued at approximately $174,000, acquiring 646 shares of the company's stock.
• CEO Yvonne Greenstreet sold 31,640 shares worth nearly $9.6 million, significantly reducing her ownership by 39.26% and leaving her with around 48,948 shares.
• Analyst ratings for Alnylam Pharmaceuticals show a strong optimistic outlook, with the average target price raised to $403.92 and a consensus rating of "Moderate Buy" based on recent brokerage reports.

Zions Bancorporation National Association UT purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 646 shares of the biopharmaceutical company's stock, valued at approximately $174,000.

A number of other large investors also recently modified their holdings of the company. Swiss National Bank lifted its stake in shares of Alnylam Pharmaceuticals by 0.4% in the 1st quarter. Swiss National Bank now owns 364,200 shares of the biopharmaceutical company's stock valued at $98,341,000 after acquiring an additional 1,600 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in Alnylam Pharmaceuticals by 11.8% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 105,879 shares of the biopharmaceutical company's stock worth $28,589,000 after purchasing an additional 11,181 shares during the last quarter. Altfest L J & Co. Inc. bought a new position in Alnylam Pharmaceuticals during the 1st quarter worth $284,000. Charles Schwab Investment Management Inc. raised its position in Alnylam Pharmaceuticals by 7.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 554,606 shares of the biopharmaceutical company's stock worth $149,755,000 after purchasing an additional 40,644 shares during the last quarter. Finally, ASR Vermogensbeheer N.V. bought a new position in Alnylam Pharmaceuticals during the 1st quarter worth $2,366,000. 92.97% of the stock is currently owned by institutional investors.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 31,640 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the transaction, the chief executive officer owned 48,948 shares of the company's stock, valued at $14,899,281.72. This trade represents a 39.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.20% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $438.93 on Monday. The company has a market capitalization of $57.53 billion, a P/E ratio of -177.70 and a beta of 0.25. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $439.36. The business has a 50-day simple moving average of $331.79 and a two-hundred day simple moving average of $284.89.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. The business had revenue of $773,689 billion during the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%. The company's quarterly revenue was up 17.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.13) EPS. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ALNY. JPMorgan Chase & Co. raised their target price on Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 6th. Morgan Stanley raised their target price on Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. Barclays raised their target price on Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the stock an "overweight" rating in a research report on Friday, August 1st. BMO Capital Markets raised their target price on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 24th. Finally, Scotiabank raised their target price on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a "sector outperform" rating in a research report on Friday, August 1st. Four equities research analysts have rated the stock with a hold rating, twenty-three have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $403.92.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.